Cancer
AutoGenomics
The company's mission is to empower clinical laboratories with an automated multiplexing MDx solution to perform molecular testing that will significantly enhance work flow, cost efficiency and turn-around time resulting in enhanced patient care.
HPV
The INFINITI® HPV Genotyping test genotypes 13 high risk HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66) plus 7 intermediate risk HPVs (26, 53, 67, 68, 69, 73, 82) and 6 low risk HPVs (6, 11, 30, 34, 70 and 85).
Other INFINITI® cancer tests are 2D6T (Tamoxifen), MDR1 (multi drug resistance), UGT1A1 (Irinotecan), 5-FU (5-Fluorouracil), CHEK-2, KRAS-BRAF, EGFR (coming soon).
.
HPV-HR QUAD (Human Papillomavirus) |
[PDF 800KB] |
NAT2 (N-acetyltransferase 2) |
[PDF 800KB] |
CHEK2 (Checkpoint Kinase 2) |
[PDF 800KB] |
5-FU (5-Fluorouracil) |
[PDF 800KB] |
KRAS |
[PDF 800KB] |
BRAF |
[PDF 800KB] |
KRAS - BRAF |
[PDF 800KB] |
BRAF XP |
[PDF 800KB] |
EGFR |
[PDF 800KB] |
TAMX3 |
[PDF 800KB] |
Breast Cancer Ashkenazi Jewisch (BCP-AJ) |
[PDF 800KB] |
Contact
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch
| Your local distributor Order About us Job opportunities |
Search
News
The recently launched EntroGen BRAF (V600E/K/D) test, that can be run on your real-time PCR instrument, is now CE-IVD marked
The EntroGen BRAF (V600E/K/D) test is a very useful tool for the detection of important mutations found in melanoma, because it detects, beside the V600E more
INFINITI KRAS-BRAF study from the Basel Institut of Pathology published in the Diagnostic Molecular Pathology journal.
New publication about the INFINITI KRAS assay in the Journal Diagn Mol Path 21/1 2012 14-23, Bihl et al. In this study from the Institute of Pathology at more
Recent publications on BÜHLMANN calprotectin assays
Three very interesting new papers have been published recently. Manz et al. describes the quality and usefulness of the BÜHLMANN calprotectin ELISA in an more
NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND
BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb more
BÜHLMANN Core | BÜHLMANN Molecular | BÜHLMANN Medical | Customer Relations | About Us |
Contact |